Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000502289 | SCV000595988 | uncertain significance | not specified | 2016-09-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001350130 | SCV001544508 | uncertain significance | Cernunnos-XLF deficiency | 2022-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 100 of the NHEJ1 protein (p.Val100Ala). This variant is present in population databases (rs201186145, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with NHEJ1-related conditions. ClinVar contains an entry for this variant (Variation ID: 435983). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NHEJ1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004023388 | SCV004988195 | uncertain significance | Inborn genetic diseases | 2023-12-15 | criteria provided, single submitter | clinical testing | The c.299T>C (p.V100A) alteration is located in exon 3 (coding exon 2) of the NHEJ1 gene. This alteration results from a T to C substitution at nucleotide position 299, causing the valine (V) at amino acid position 100 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |